Mayo Clinic Trial Tests NR Supplement on Aging Muscle, Bone and Metabolism
A completed Mayo Clinic trial examined whether nicotinamide riboside can preserve bone density, muscle mass, and metabolic function in healthy older adults.
Summary
As we age, we lose muscle mass, bone density, and metabolic efficiency — a trio of changes that drives frailty and disease. Nicotinamide riboside (NR), a form of vitamin B3, boosts NAD+ levels in the body, a molecule critical for cellular energy production that declines with age. This completed Mayo Clinic clinical trial enrolled healthy elderly volunteers to test whether NR supplementation could counter these age-related declines in bone, skeletal muscle, and metabolic function. Participants received either NR or a placebo, allowing researchers to isolate NR's effects. The trial represents an important step in evaluating whether NAD+ precursor supplementation can translate laboratory findings — where NR has shown promise in animal models — into real, measurable benefits for aging humans.
Detailed Summary
Age-related decline in NAD+ (nicotinamide adenine dinucleotide) levels is increasingly recognized as a central driver of physiological aging. NAD+ is essential for mitochondrial energy production, DNA repair, and activation of sirtuins — proteins linked to longevity. Nicotinamide riboside (NR), a natural vitamin B3 derivative, is one of the most bioavailable precursors for restoring NAD+ levels in tissues, making it a leading candidate for anti-aging supplementation. This completed phase NA randomized controlled trial, sponsored by Mayo Clinic and registered under NCT03818802, set out to rigorously test NR's impact on three domains closely tied to healthspan: bone structure, skeletal muscle mass and function, and metabolic health in elderly individuals.
The trial enrolled healthy elderly volunteers and compared NR supplementation against placebo, allowing for a controlled assessment of NR's biological effects in an aging human population. The focus on bone, muscle, and metabolism is clinically significant, as sarcopenia and osteoporosis together account for enormous burden of disability, falls, and fractures in older adults, while metabolic dysfunction underpins chronic disease risk.
Preclinical studies in rodents have demonstrated that NR supplementation can improve muscle function, increase mitochondrial biogenesis, and support bone density. Human trials have confirmed that NR reliably raises blood NAD+ levels, but functional outcomes — the outcomes that actually matter to patients — have been less clearly established. This Mayo Clinic study was designed to close that gap.
The trial has been completed, though full results have not been published in the available abstract. The outcome will be pivotal for the field: if NR demonstrates measurable improvements in muscle, bone, or metabolic parameters, it would provide strong clinical justification for NR as a mainstream aging intervention.
Physicians and health-conscious individuals await peer-reviewed results. Until then, NR remains a promising but not fully validated intervention for musculoskeletal aging.
Key Findings
- Trial tested NR supplementation vs. placebo specifically for bone, muscle, and metabolic outcomes in elderly adults.
- Mayo Clinic sponsorship lends institutional rigor to this NAD+ precursor efficacy evaluation.
- Healthy elderly volunteers were recruited, targeting the population most likely to benefit from NAD+ restoration.
- NR reliably raises NAD+ levels in humans, but whether this translates to functional aging benefits remains under investigation.
- Trial is completed — full published results will be critical for guiding NR supplementation recommendations.
Methodology
This was a completed randomized controlled trial (Phase NA) comparing nicotinamide riboside to placebo in healthy elderly volunteers, sponsored by Mayo Clinic. The trial assessed effects on bone structure, skeletal muscle, and metabolic function, though specific endpoint measures, sample size, dosing regimen, and duration are not disclosed in the available abstract.
Study Limitations
This summary is based on the abstract only; full methodology, results, adverse events, sample size, dosing, and duration are not available. The trial is listed as completed but peer-reviewed results have not been published or were not accessible at the time of this summary. Without outcome data, no conclusions about NR's efficacy can be drawn from this entry alone.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.